Asia-Pacific anti-hypertensive therapeutics market to hit $ 27 bn dollars by 2022: GBI Research
Growth will not be aided by the weak anti-hypertensive pipeline, due to lack of innovative products in late-stage development
Author
Sun Pharma completes acquisition of JSC Biosintez
Russia-based Biosintez focuses on the hospital segment with annual revenues of about $52 million for 2015
Experts examine the strategies for a new VUCA WORLD
Featuring
- Jawed Zia, Novartis India
- Mike Warmuth, Abbott
- Daara Patel, IDMA
- Dr Ajit Dangi, Danssen Consulting
- Utkarsh…
Embracing change: Crucial to success in a VUCA world
Jawed Zia, Country President, Novartis India, advises pharma leaders to constantly evaluate their skills and course correct to…
India: The pulse of healthcare in emerging economies
India was among the first countries in which Abbott expanded outside the US, way back in 1910. Today, more than 85 per cent of…
Navigating through turbulent waters
Dr Ajit Dangi, President & CEO Danssen Consulting, shares his tips for pharma leaders to operate and thrive in a VUCA world…
Trends and challenges in a VUCA world
Utkarsh Palnitkar, Partner, National Head – Infrastructure, Government & Healthcare National Head – Life Sciences practice,…
Leadership strategy to SAVE clinical trials in India from VUCA
Dr Arun Bhatt, Consultant – Clinical Research & Development, advocates the need for collective leadership which focusses on…
68th IPCE to be held in Hyderabad
Delegates from across the world will congregate in Visakhapatnam from December 16 to 18, 2016
India Pharma 2017 to be held in Bengaluru
The event from February 9-11, 2017, will be an international exhibition and conference on pharma industry